Hospital
Lodi Memorial Hospital Association INC
Lodi Memorial Hospital Association INC was paid $36.78M by Medicaid between Jan 2018 and Dec 2024, across 290 billing codes. Its largest line is 0450, Emergency room services — 16% of everything it billed.
33Billing provider infoLODI MEMORIAL HOSPITAL ASSOCIATION INC
LODI, CA 95240
LODI, CA 95240
33aNPI1316938301assigned 10/31/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$36.78M
24GClaims1,349,158
24DCodes billed290
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in California
Rank by total paid#80 of 410
Median peer was paid$6.90M
This provider vs. median5.3×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 182,351 | $4.69M | |
| 2019 | 191,111 | $4.72M | |
| 2020 | 133,686 | $3.60M | |
| 2021 | 164,926 | $4.51M | |
| 2022 | 216,825 | $6.36M | |
| 2023 | 246,457 | $6.63M | |
| 2024incomplete | 213,802 | $6.28M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0450 | Emergency room services | 16% | 127,318 | 113,259 | $5.93M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 4.7% | 7,607 | 7,479 | $1.74M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 3.5% | 17,516 | 16,989 | $1.29M |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 3.3% | 16,747 | 16,300 | $1.21M |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 2.8% | 6,874 | 6,691 | $1.04M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.7% | 14,571 | 13,574 | $979K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.1% | 8,170 | 7,978 | $787K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.8% | 32,114 | 29,317 | $644K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.7% | 10,739 | 10,478 | $634K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.7% | 9,474 | 8,413 | $611K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.6% | 12,432 | 11,304 | $606K |
| 0250 | 1.6% | 45,857 | 26,219 | $590K |
278 more codes
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 1.6% | 47,905 | $574K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 1.5% | 1,975 | $564K |
| 80053 | Comprehensive metabolic panel | 1.5% | 65,190 | $563K |
| 97597 | 1.4% | 17,062 | $532K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.4% | 17,342 | $506K |
| 0516 | 1.4% | 16,756 | $498K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.3% | 4,007 | $473K |
| 71046 | Radiologic examination, chest; 2 views | 1.3% | 21,610 | $463K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.2% | 68,091 | $432K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.1% | 5,165 | $417K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.1% | 2,494 | $412K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.1% | 5,941 | $412K |
| 97598 | 1.1% | 1,567 | $397K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.1% | 21,250 | $395K |
| 0360 | 1.0% | 2,595 | $379K | |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.0% | 12,725 | $368K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 12,309 | $356K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 11,856 | $355K |
| 0510 | <1% | 11,402 | $337K | |
| 99199 | Unlisted special service, procedure or report | <1% | 5,096 | $336K |
| Z7502 | <1% | 8,464 | $314K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 11,208 | $301K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 7,099 | $294K |
| J3490 | Unclassified drugs | <1% | 18,981 | $289K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 15,998 | $280K |
| 0761 | <1% | 8,258 | $238K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 14,377 | $235K |
| 99284 | Emergency room visit (serious) | <1% | 4,880 | $226K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 8,464 | $224K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,254 | $224K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,320 | $223K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 3,810 | $220K |
| T1999 | Miscellaneous therapeutic items and supplies, retail purchases, not otherwise classified; identify product in "remarks" | <1% | 13,518 | $220K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,647 | $213K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 6,700 | $205K |
| Z7500 | <1% | 6,040 | $203K | |
| 76830 | Ultrasound, transvaginal | <1% | 3,307 | $195K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 10,242 | $195K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,791 | $187K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,042 | $181K |
| 76801 | <1% | 2,989 | $178K | |
| 99283 | Emergency room visit (moderate) | <1% | 4,058 | $178K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 15,092 | $165K |
| 93971 | <1% | 1,925 | $162K | |
| 71045 | Radiologic examination, chest; single view | <1% | 13,718 | $162K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,834 | $156K |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 5,236 | $156K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 3,129 | $153K |
| 84484 | <1% | 18,594 | $147K | |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 3,771 | $140K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 14,765 | $138K |
| 83690 | <1% | 23,076 | $137K | |
| 83880 | <1% | 5,705 | $133K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 6,609 | $132K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 2,125 | $132K |
| 81001 | <1% | 46,323 | $129K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 10,397 | $128K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 4,196 | $128K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 4,194 | $127K |
| 99285 | Emergency room visit (most serious) | <1% | 2,808 | $125K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 6,923 | $119K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 17,769 | $115K |
| 97750 | <1% | 2,631 | $110K | |
| 99239 | Hospital discharge day management, more than 30 minutes | <1% | 2,294 | $106K |
| 83605 | <1% | 11,697 | $105K | |
| 87631 | <1% | 1,355 | $99K | |
| 87040 | <1% | 10,042 | $93K | |
| 84702 | <1% | 6,641 | $82K | |
| 99070 | <1% | 4,691 | $80K | |
| 73562 | <1% | 3,838 | $77K | |
| 0760 | <1% | 3,091 | $75K | |
| 73610 | <1% | 3,275 | $74K | |
| 0160 | <1% | 189 | $73K | |
| 73630 | <1% | 3,427 | $71K | |
| Z1034 | <1% | 993 | $69K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 1,511 | $67K |
| 73030 | <1% | 3,046 | $64K | |
| 84145 | <1% | 5,249 | $63K | |
| 0270 | <1% | 8,204 | $61K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 738 | $61K |
| 90715 | <1% | 1,441 | $61K | |
| 81025 | <1% | 15,405 | $60K | |
| 73130 | <1% | 2,538 | $58K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 899 | $56K |
| 72131 | <1% | 491 | $54K | |
| 99223 | Prolong inpt eval add15 m | <1% | 826 | $53K |
| 99152 | <1% | 1,534 | $51K | |
| 73110 | <1% | 2,150 | $49K | |
| 0729 | <1% | 1,615 | $48K | |
| 84703 | <1% | 7,950 | $48K | |
| 83735 | <1% | 8,169 | $45K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,263 | $45K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 4,493 | $45K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 5,412 | $44K |
| 82805 | <1% | 1,922 | $44K | |
| 70486 | <1% | 355 | $43K | |
| 0762 | <1% | 66 | $41K | |
| 73502 | <1% | 1,293 | $40K | |
| 86140 | <1% | 8,845 | $39K | |
| 76857 | <1% | 1,372 | $38K | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 3,378 | $38K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 5,354 | $37K |
| 87634 | <1% | 499 | $35K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 3,825 | $35K |
| 72100 | <1% | 1,285 | $34K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 29 | $33K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 184 | $33K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 665 | $32K |
| 85610 | <1% | 10,102 | $32K | |
| 87186 | <1% | 4,433 | $32K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 650 | $32K |
| 70496 | <1% | 153 | $31K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 1,311 | $30K |
| Z9725 | <1% | 693 | $30K | |
| 0636 | <1% | 2,758 | $29K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 4,489 | $28K |
| 70498 | <1% | 154 | $28K | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,087 | $28K |
| 97116 | <1% | 2,164 | $28K | |
| 74018 | <1% | 1,353 | $28K | |
| 87081 | <1% | 4,877 | $27K | |
| 73080 | <1% | 1,080 | $27K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 6,937 | $27K |
| 76770 | <1% | 409 | $26K | |
| 99499 | <1% | 465 | $26K | |
| 81514 | <1% | 104 | $26K | |
| 0710 | <1% | 563 | $26K | |
| 80179 | <1% | 1,489 | $25K | |
| 80143 | <1% | 1,510 | $25K | |
| 73590 | <1% | 1,108 | $25K | |
| 71250 | <1% | 218 | $21K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 4,822 | $21K |
| 85379 | <1% | 2,157 | $20K | |
| 85027 | <1% | 3,813 | $20K | |
| 85730 | <1% | 4,300 | $20K | |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 288 | $19K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 2,896 | $19K |
| 95816 | <1% | 402 | $19K | |
| 76870 | <1% | 395 | $18K | |
| 81003 | <1% | 8,041 | $17K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 307 | $17K |
| 82550 | <1% | 3,078 | $17K | |
| J1815 | Injection, insulin, per 5 units | <1% | 1,156 | $17K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,772 | $17K |
| 87077 | <1% | 2,563 | $17K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,733 | $15K |
| 99460 | <1% | 297 | $14K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 82 | $14K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,898 | $14K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,567 | $14K |
| 96367 | <1% | 281 | $14K | |
| 73090 | <1% | 774 | $13K | |
| 94726 | <1% | 287 | $13K | |
| 73564 | <1% | 814 | $13K | |
| 93970 | <1% | 99 | $12K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 808 | $12K |
| 82962 | <1% | 4,416 | $12K | |
| 94060 | <1% | 394 | $12K | |
| 94729 | <1% | 262 | $12K | |
| 87088 | <1% | 2,071 | $12K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 404 | $11K |
| 74019 | <1% | 462 | $11K | |
| 0456 | <1% | 296 | $11K | |
| 82948 | <1% | 4,326 | $10K | |
| 86901 | <1% | 3,978 | $10K | |
| 87070 | <1% | 1,381 | $9K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 831 | $9K |
| 86900 | <1% | 3,983 | $9K | |
| 86780 | <1% | 880 | $9K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 88 | $9K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 364 | $9K |
| 86769 | <1% | 230 | $9K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 116 | $8K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 453 | $8K |
| J2704 | Injection, propofol, 10 mg | <1% | 743 | $8K |
| 85007 | <1% | 3,281 | $8K | |
| 87210 | <1% | 2,166 | $8K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,100 | $7K |
| 94644 | <1% | 317 | $7K | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 2,073 | $7K |
| Z6410 | <1% | 521 | $6K | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 462 | $6K |
| 86850 | <1% | 1,919 | $6K | |
| Z7610 | <1% | 1,719 | $6K | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 37 | $6K |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 26 | $6K |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 64 | $6K |
| 0259 | <1% | 6,914 | $5K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 727 | $5K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 45 | $5K |
| 80061 | Lipid panel | <1% | 569 | $5K |
| 82010 | <1% | 750 | $5K | |
| 73140 | <1% | 343 | $5K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 945 | $5K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 880 | $4K |
| 70491 | <1% | 28 | $4K | |
| 84439 | <1% | 570 | $4K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 219 | $4K |
| 0001A | <1% | 103 | $4K | |
| 95819 | <1% | 126 | $4K | |
| 76536 | <1% | 78 | $4K | |
| 72110 | <1% | 106 | $4K | |
| 97124 | <1% | 331 | $4K | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 104 | $4K |
| 0324 | <1% | 39 | $4K | |
| 59025 | Fetal non-stress test | <1% | 202 | $4K |
| 87807 | <1% | 444 | $4K | |
| 85652 | <1% | 1,499 | $3K | |
| 72040 | <1% | 162 | $3K | |
| 90670 | <1% | 427 | $3K | |
| 90723 | <1% | 358 | $3K | |
| 90647 | <1% | 347 | $3K | |
| Z1032 | <1% | 13 | $2K | |
| 72128 | <1% | 24 | $2K | |
| 0002A | <1% | 55 | $2K | |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 71 | $2K |
| 86413 | <1% | 32 | $2K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 29 | $2K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 184 | $2K |
| 87205 | <1% | 567 | $2K | |
| 90681 | <1% | 197 | $2K | |
| 71101 | <1% | 62 | $2K | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 219 | $2K |
| 94664 | <1% | 147 | $2K | |
| 71100 | <1% | 70 | $1K | |
| 86480 | <1% | 27 | $1K | |
| 73560 | <1% | 92 | $1K | |
| 0011A | <1% | 35 | $1K | |
| Z6400 | <1% | 27 | $1K | |
| 87147 | <1% | 328 | $1K | |
| 36600 | <1% | 355 | $1K | |
| 71020 | <1% | 48 | $1K | |
| 97035 | <1% | 159 | $1K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 50 | $1K |
| 94760 | <1% | 196 | $1K | |
| 85018 | <1% | 468 | $1K | |
| 73060 | <1% | 55 | $943.08 | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 15 | $687.57 |
| 84132 | <1% | 223 | $682.87 | |
| 73552 | <1% | 39 | $631.33 | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 26 | $623.82 |
| 86923 | <1% | 13 | $609.24 | |
| 0012A | <1% | 14 | $560.00 | |
| 92552 | <1% | 56 | $555.35 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 29 | $536.42 |
| 90688 | <1% | 22 | $490.60 | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 54 | $490.25 |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 12 | $481.70 |
| V5008 | Hearing screening | <1% | 12 | $450.00 |
| 80076 | <1% | 71 | $440.04 | |
| 73620 | <1% | 25 | $425.15 | |
| 90662 | <1% | 36 | $424.42 | |
| 73100 | <1% | 26 | $400.42 | |
| 84295 | <1% | 127 | $395.92 | |
| 99462 | <1% | 15 | $377.99 | |
| 82435 | <1% | 126 | $348.81 | |
| 87640 | <1% | 12 | $276.91 | |
| 86308 | <1% | 62 | $264.37 | |
| 84100 | <1% | 76 | $260.47 | |
| 97150 | Therapeutic procedure(s), group (2 or more individuals) | <1% | 1,076 | $257.22 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 14 | $197.47 |
| 86762 | <1% | 12 | $195.72 | |
| 69209 | <1% | 28 | $150.00 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 16 | $139.68 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 14 | $133.70 |
| 82150 | <1% | 27 | $129.55 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 14 | $126.80 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 15 | $123.96 |
| 84550 | <1% | 24 | $92.97 | |
| 84156 | <1% | 28 | $88.02 | |
| 82570 | <1% | 14 | $59.80 | |
| 83615 | <1% | 12 | $57.81 | |
| J7611 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg | <1% | 121 | $43.46 |
| 90658 | <1% | 12 | $27.00 | |
| 87340 | <1% | 12 | $14.76 | |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 113 | $6.83 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 0% | 12 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDELMORE, KATIE (FINANCE OFFICER)